Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program

To collect efficacy and safety data of enzalutamide after docetaxel, we retrospectively evaluated the Italian Named Patient Program results.

Two hundred and nine metastatic castration-resistant prostate cancer patients were enrolled. Median age was 73 years. Total 42.1% patients had pain, 14.4% had a performance status of two and 59.8% had a Gleason score ≥8. Total 31.1% had previously received ≥2 chemotherapies, 15.3 and 12% had been previously treated with abiraterone and cabazitaxel, respectively and 14.8% had received both.

 Median progression-free survival and overall survival were 4.8 and 13.1 months, respectively. A prostate-specific antigen reduction ≥50% was observed in 49.1%. Total 32.7% abiraterone-pretreated patients achieved a biochemical response compared with 56% of abiraterone-naive patients.

 Enzalutamide was safe and well tolerated. Its antitumor activity in abiraterone-pretreated patients was limited.

Future oncology (London, England). 2018 Sep 12 [Epub ahead of print]

Francesca Maines, Ugo De Giorgi, Giuseppe Procopio, Gaetano Facchini, Lucia Fratino, Roberto Sabbatini, Donatello Gasparro, Umberto Basso, Claudia Mosillo, Enrico Campadelli, Francesco Massari, Teodoro Sava, Suzana Sirotova, Caterina Messina, Sarah Scagliarini, Vincenza Conteduca, Elena Verzoni, Sabrina Rossetti, Antonello Veccia, Stefania Kinspergher, Orazio Caffo

Medical Oncology, S Chiara Hospital, Largo Medaglie d'Oro 1, Trento, Italy., Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy., Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, via Venezian 1, Milano, Italy., Medical Oncology, Istituto Nazionale dei Tumori - IRCCS, Fondazione 'G Pascale', via Semmola 49, Napoli, Italy., Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano, via F. Gallini 2, Aviano - Pordenone, Italy., Department of Oncology & Hematology, Azienda Ospedaliero - Universitaria di Modena, via del pozzo 71, Italy., Medical Oncology, Ospedale Maggiore di Parma, via Gramsci 14, Parma, Italy., UOC Oncologia Medica 1, Istituto Oncologico Veneto IRCCS, via Gattamelata 64, Padova., Department of Radiology, Oncology & Human Pathology, Sapienza, Università di Roma, Roma, Italy., Medical Oncology, Faenza Hospital, viale Stradone 9, Faenza, Italy., Division of Oncology, S Orsola-Malpighi Hospital, via Albertoni 15, Bologna, Italy., Medical Oncology, Ospedale di Camposampiero, ULSS Alta Padovana, Cittadella, Italy., Medical Oncology, Parini Hospital, Viale Ginevra 3, Aosta, Italy., Medical Oncology, ASST Papa Giovanni XXIII Bergamo Hospital, Piazza OMS 1, Bergamo, Italy., Medical Oncology, Azienda Ospedaliera di Rilievo Nazionale Cardarelli, via Cardarelli 9, Napoli, Italy.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.